vedolizumab

November 6, 2017November 6, 2017

Real-world Data Continues Showing Benefits of Takeda’s Entyvio for IBD Patients

News

Real-world data demonstrates the safety, tolerability, and efficacy of Entyvio (vedolizumab) in treating ulcerative colitis (UC) and Crohn’s disease, confirming previous data collected in clinical trials. These findings were the ... Read more

October 18, 2017

Entyvio Eased Early Symptoms of Ulcerative Colitis and Crohn’s, New Analysis Shows

News

Entyvio (vedolizumab) alleviated some of the early symptoms of patients with moderate to severe ulcerative colitis and Crohn’s disease, a new analysis of Phase 3 trial results indicates. Takeda Pharmaceutical presented the ... Read more

August 24, 2017August 25, 2017

Takeda Asks Japanese Regulators to Approve Vedolizumab as an Ulcerative Colitis Treatment

News

Takeda Pharmaceutical Company has submitted a new drug application to Japanese regulators for vedolizumab (MLN0002) as a treatment for adults with moderate to severe ulcerative colitis. Ulcerative colitis “is a chronic, ... Read more

June 14, 2017

More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says

News

More inflammatory bowel disease patients are switching biologic therapies than in 2016, according to a report by Spherix Global Insights RealWorld Dynamix. The appearance of Janssen’s Stelara (ustekinumab) — approved ... Read more

May 24, 2017

Miraca’s InformTx Treatment Response Platform for IBD Now Includes Testing for Inflectra

News

Miraca Life Sciences‘ InformTx testing helps doctors assess the response of patients with inflammatory bowel disease (IBD) to certain drug treatments. The company has now expanded its therapeutic drug monitoring ... Read more

February 22, 2017

Entyvio for IBD Shows Promising Safety Results in Long-term Clinical Trial

News

Takeda Pharmaceuticals recently presented positive five-year results of an eight-year clinical trial (NCT00790933) evaluating the long-term safety of Entyvio (vedolizumab) in patients with active ulcerative colitis and Crohn’s disease, two of the ... Read more

March 4, 2016March 4, 2016

Patients with Crohn’s and Ulcerative Colitis Show Promising Results in Entyvio Clinical Trials

News

Recently compiled safety data from all clinical trials on Entyvio (vedolizumab) for patients with inflammatory bowel disease (IBD) show the drug is associated with low rates of new serious infections, infusion-related reactions, and cancers. ... Read more

December 26, 2014December 26, 2014

NICE: Entyvio for Crohn’s Disease Needs More Supporting Evidence

Crohn's Disease, News

The provider of national guidance and advice to improve health and social care in the United Kingdom, the National Institute for Health and Care Excellence (NICE), recently ruled against the approval of Entyvio ... Read more

December 1, 2014December 1, 2014

Entyvio by Takeda UK is First UC Maintenance to Receive NICE Approval

News, Ulcerative colitis

Takeda UK, a subsidiary of Japan’s leading pharmaceutical company, recently achieved a pioneering milestone when the National Institute for Health and Care Excellence (NICE) granted Entyvio® (vedolizumab) a positive provisional recommendation in the ... Read more

November 5, 2014November 5, 2014

IBD Drug Entyvio By Takeda Pharmaceuticals Is Not Proved According to IQWiG

News

In an evaluation in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) recently assessed whether ... Read more